A Seoul-based biotech preclinical and clinical stage company specializes in the ultimate form of TLR3 agonist as a novel immunostimulant for diverse applications, from vaccine adjuvants to vaccine and immunotherapy.

The major pipelines are:

1)   Myalgic Encephalomyelitis, chronic fatigue syndrome (ME/CFS) therapy

2)   Multiple Sclerosis therapy

3)   Zoster vaccine with a safer and stronger IgG and CD4 T-cell response than Shingrix

4)   CMV therapeutic vaccine for allogenic Hematopoietic Stem Cell transplantation.

5)   Adjuvant therapy for highly metastatic cancer after surgical dissection